The understanding and management of severe skin disorders have significantly evolved over the past century. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), identified by Stevens and Johnson in 1922, represent a spectrum of conditions ranging from mild to life-threatening. The identification of causative agents, particularly drugs, is crucial for effective patient care. However, previous research has been hampered by inconsistent diagnostic methods, leading to unreliable conclusions about the causes of these disorders.

In various regions, the occurrence of SJS/TEN differs markedly. For example, European and American studies report an incidence of approximately 1-2 cases per million people annually for TEN. In contrast, Asian data remains less comprehensive, with significant gaps in reporting. This variability underscores the need for standardized diagnostic tools such as the Roussel Uclaf Causality Assessment Method (RUCAM) and the Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN). These tools provide structured frameworks to evaluate drug-induced liver injury, enhancing diagnostic accuracy. Despite their utility, these methods are often underutilized in clinical practice, resulting in incomplete or inaccurate diagnoses.

A novel classification system has been introduced to bring clarity to the diagnosis and treatment of SJS/TEN. This system categorizes cases into five types based on causative factors and diagnostic algorithms used. By providing consistent criteria, this typology aims to improve patient management and facilitate more systematic research. Standardized diagnostic tools enable better differentiation between drug-induced and non-drug-induced cases, leading to targeted and effective treatment strategies. Future research should focus on expanding the application of these diagnostic algorithms, especially in underreported areas, to enhance our understanding of SJS/TEN and its relationship to liver injury.

Embracing validated causality assessment tools like RUCAM and ALDEN represents a significant step forward in diagnosing and treating SJS/TEN. Accurate diagnoses and optimized treatment strategies can ultimately lead to improved patient outcomes. Through consistent application of these tools, clinicians can provide more precise care, ensuring better health results for those affected by these severe skin disorders.